X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (10196) 10196
Book Review (3937) 3937
Newsletter (2687) 2687
Publication (952) 952
Newspaper Article (225) 225
Book Chapter (94) 94
Conference Proceeding (53) 53
Magazine Article (40) 40
Transcript (25) 25
Trade Publication Article (14) 14
Book / eBook (9) 9
Dissertation (7) 7
Reference (7) 7
Report (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (7863) 7863
humans (7188) 7188
monoclonal antibodies (6844) 6844
rituximab (4375) 4375
antibodies, monoclonal - therapeutic use (2461) 2461
cancer (2355) 2355
research (2341) 2341
oncology (2313) 2313
female (2299) 2299
male (2110) 2110
animals (2106) 2106
monoclonal-antibody (2021) 2021
care and treatment (1825) 1825
middle aged (1702) 1702
antibodies, monoclonal, murine-derived (1669) 1669
hematology (1627) 1627
immunotherapy (1570) 1570
anti-cd20 monoclonal-antibody (1569) 1569
immunology (1569) 1569
adult (1543) 1543
therapy (1462) 1462
aged (1336) 1336
non-hodgkins-lymphoma (1320) 1320
treatment outcome (1304) 1304
lymphomas (1236) 1236
pharmacology & pharmacy (1131) 1131
health aspects (1127) 1127
antineoplastic agents - therapeutic use (1102) 1102
reports (1013) 1013
chemotherapy (1012) 1012
drug therapy (993) 993
biological products (952) 952
monoclonal antibody (934) 934
antineoplastic agents (918) 918
mice (899) 899
analysis (897) 897
chronic lymphocytic-leukemia (893) 893
antimitotic agents (879) 879
medical research (871) 871
immunoglobulins (868) 868
rheumatoid arthritis (868) 868
antibodies, monoclonal - administration & dosage (860) 860
lymphoma (806) 806
monoclonal-antibodies (794) 794
double-blind (785) 785
clinical trials (774) 774
universities and colleges (773) 773
antibodies (759) 759
antineoplastic combined chemotherapy protocols - therapeutic use (747) 747
b-cell lymphoma (718) 718
rheumatology (709) 709
transplantation (687) 687
patients (680) 680
medicine & public health (674) 674
antibodies, monoclonal - adverse effects (670) 670
antibodies, monoclonal - pharmacology (656) 656
abridged index medicus (644) 644
medicine, experimental (639) 639
rheumatoid-arthritis (627) 627
proteins (617) 617
medicine, research & experimental (599) 599
antibodies, monoclonal - immunology (591) 591
in-vivo (586) 586
b cells (566) 566
antigens, cd20 - immunology (562) 562
drugs (557) 557
b-lymphocytes - immunology (540) 540
antibodies, monoclonal, murine-derived - therapeutic use (539) 539
apoptosis (539) 539
tumors (538) 538
follicular lymphoma (536) 536
immunologic factors - therapeutic use (528) 528
non-hodgkin's lymphomas (528) 528
clinical trials as topic (525) 525
antigens (506) 506
cell line, tumor (504) 504
cd20 (501) 501
cytotoxicity (499) 499
review (487) 487
disease (483) 483
leukemia (478) 478
aged, 80 and over (477) 477
article (474) 474
t cells (474) 474
infliximab (470) 470
lymphocytes (468) 468
efficacy (464) 464
prognosis (458) 458
expression (450) 450
arthritis, rheumatoid - drug therapy (432) 432
immunosuppressive agents - therapeutic use (431) 431
rheumatoid factor (425) 425
safety (421) 421
antibodies, monoclonal, humanized (420) 420
viral antibodies (416) 416
adolescent (414) 414
systemic-lupus-erythematosus (413) 413
biotechnology & applied microbiology (411) 411
antineoplastic agents - pharmacology (405) 405
autoimmunity (403) 403
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (12617) 12617
Japanese (330) 330
Chinese (136) 136
French (59) 59
German (54) 54
Spanish (33) 33
Polish (15) 15
Russian (13) 13
Czech (10) 10
Korean (6) 6
Turkish (3) 3
Portuguese (2) 2
Slovak (2) 2
Hungarian (1) 1
Serbian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


British Journal of Haematology, ISSN 0007-1048, 12/2015, Volume 171, Issue 5, pp. 763 - 775
Obinutuzumab is a novel glycoengineered Type‐ II CD 20 monoclonal antibody. CD 20 is expressed in approximately 100% of children and adolescents with Burkitt... 
ALL | pre‐B | BL | rituximab‐sensitive | rituximab‐resistant | obinutuzumab | rituximab | Rituximab | Obinutuzumab | Pre-B-ALL | Rituximab-sensitive BL | Rituximab-resistant BL | pre-B-ALL | NATURAL-KILLER-CELLS | ONCOLOGY GROUP-REPORT | rituximab-sensitive BL | rituximab-resistant ill | PHASE I/II | CHEMOTHERAPY PLUS RITUXIMAB | CHILDREN | IN-VITRO | ANTI-CD20 MONOCLONAL-ANTIBODY | NON-HODGKIN-LYMPHOMA | CHRONIC LYMPHOCYTIC-LEUKEMIA | RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA | HEMATOLOGY | Neoplasm Transplantation | Apoptosis - drug effects | Humans | Transplantation, Heterologous | Rituximab - pharmacology | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Animals | Caspases - metabolism | Antibodies, Monoclonal, Humanized - pharmacology | Survival Analysis | Cell Line, Tumor | Caspases - drug effects | Lysosomal-Associated Membrane Protein 1 - metabolism | Antineoplastic Agents - pharmacology | Cell Proliferation - drug effects | Killer Cells, Natural - drug effects | Mice | Interferon-gamma - biosynthesis | Molecular Targeted Therapy - methods | Burkitt Lymphoma - drug therapy | Disease Models, Animal | Drug Resistance, Neoplasm - drug effects | Antimitotic agents | Evaluation | Cell death | Patient outcomes | Monoclonal antibodies | Biochemistry | Comparative analysis | Antineoplastic agents | Burkitt's lymphoma | Index Medicus
Journal Article
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9806, pp. 1858 - 1867
Summary Background The outcome of diffuse large B-cell lymphoma has been substantially improved by the addition of the anti-CD20 monoclonal antibody rituximab... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | MULTICENTER | RESPONSE CRITERIA | AGGRESSIVE LYMPHOMAS | POOR-PROGNOSIS | NON-HODGKINS-LYMPHOMA | REGIMEN | YOUNG-PATIENTS | ELDERLY-PATIENTS | DES-LYMPHOMES | TRANSPLANTATION | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Dose-Response Relationship, Drug | Young Adult | Vindesine - adverse effects | Adult | Female | Prednisolone | Doxorubicin - administration & dosage | Severity of Illness Index | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Risk Assessment | Rituximab | Treatment Outcome | Bleomycin - administration & dosage | Bleomycin - adverse effects | Vincristine | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - diagnosis | Maximum Tolerated Dose | Adolescent | Survival Analysis | Vindesine - administration & dosage | Doxorubicin - adverse effects | Chemotherapy | Physiological aspects | Lymphomas | B cells | Drug therapy | Methods | Cancer | Dehydrogenases | Toxicity | Population studies | Doxorubicin | Hepatitis | Randomization | Bleomycin | Motivation | Drug dosages | Neutropenia | Cell survival | Hematology | Prednisone | Survival | Patients | Lymphoma | Cyclophosphamide | Lymphocytes B | Monoclonal antibodies | CD20 antigen | Tumors | B-cell lymphoma | Clinical trials | Public speaking | Grants | Clinical medicine | Index Medicus | Abridged Index Medicus | Side effects | lymphoma | survival | International standardization | chemotherapy
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2008, Volume 358, Issue 7, pp. 676 - 688
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 01/2012, Volume 118, Issue 2, pp. 434 - 443
Journal Article
Journal Article
British Journal of Haematology, ISSN 0007-1048, 08/2016, Volume 174, Issue 4, pp. 571 - 581
Journal Article
Journal Article